Copeland Capital Management’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $30.7M | Sell |
144,784
-10,564
| -7% | -$2.07M | 0.63% | 63 |
|
|
2026
Q1 | $30.4M | Sell |
155,348
-4,289
| -3% | -$833K | 0.68% | 56 |
|
|
2025
Q4 | $27.7M | Sell |
159,637
-8,738
| -5% | -$1.59M | 0.62% | 63 |
|
|
2025
Q3 | $32.1M | Sell |
168,375
-7,889
| -4% | -$1.4M | 0.67% | 61 |
|
|
2025
Q2 | $31.7M | Sell |
176,264
-19,998
| -10% | -$3.47M | 0.65% | 62 |
|
|
2025
Q1 | $33.2M | Sell |
196,262
-3,044
| -2% | -$500K | 0.67% | 61 |
|
|
2024
Q4 | $30.1M | Sell |
199,306
-3,326
| -2% | -$517K | 0.56% | 76 |
|
|
2024
Q3 | $31.5M | Buy |
202,632
+3,865
| +2% | +$577K | 0.55% | 79 |
|
|
2024
Q2 | $27.2M | Buy |
198,767
+1,340
| +0.7% | +$184K | 0.51% | 81 |
|
|
2024
Q1 | $26.3M | Buy |
197,427
+6,638
| +3% | +$861K | 0.48% | 78 |
|
|
2023
Q4 | $26.3M | Sell |
190,789
-9,762
| -5% | -$1.28M | 0.53% | 73 |
|
|
2023
Q3 | $24.4M | Buy |
200,551
+1,650
| +0.8% | +$220K | 0.53% | 74 |
|
|
2023
Q2 | $28M | Buy |
198,901
+16,026
| +9% | +$2.21M | 0.58% | 67 |
|
|
2023
Q1 | $25.9M | Buy |
182,875
+1,592
| +0.9% | +$228K | 0.61% | 65 |
|
|
2022
Q4 | $28.4M | Buy |
181,283
+41,988
| +30% | +$6.03M | 0.75% | 58 |
|
|
2022
Q3 | $17.1M | Sell |
139,295
-289
| -0.2% | -$38.1K | 0.56% | 70 |
|
|
2022
Q2 | $18.6M | Buy |
139,584
+416
| +0.3% | +$56.7K | 0.59% | 66 |
|
|
2022
Q1 | $19M | Sell |
139,168
-2,338
| -2% | -$326K | 0.52% | 70 |
|
|
2021
Q4 | $24.5M | Sell |
141,506
-2,335
| -2% | -$355K | 0.64% | 64 |
|
|
2021
Q3 | $20.9M | Sell |
143,841
-5,465
| -4% | -$800K | 0.59% | 66 |
|
|
2021
Q2 | $19.7M | Sell |
149,306
-5,926
| -4% | -$776K | 0.59% | 68 |
|
|
2021
Q1 | $19.9M | Buy |
155,232
+8,076
| +5% | +$995K | 0.62% | 61 |
|
|
2020
Q4 | $17.5M | Sell |
147,156
-1,203
| -0.8% | -$147K | 0.69% | 57 |
|
|
2020
Q3 | $17M | Sell |
148,359
-2,428
| -2% | -$287K | 0.75% | 53 |
|
|
2020
Q2 | $17.2M | Buy |
150,787
+1,493
| +1% | +$158K | 0.89% | 49 |
|
|
2020
Q1 | $12M | Buy |
149,294
+8,813
| +6% | +$912K | 0.73% | 60 |
|
|
2019
Q4 | $15M | Buy |
140,481
+22,121
| +19% | +$2.31M | 0.66% | 55 |
|
|
2019
Q3 | $12.7M | Buy |
118,360
+2,453
| +2% | +$252K | 0.65% | 54 |
|
|
2019
Q2 | $11.8M | Buy |
115,907
+26,391
| +29% | +$2.54M | 0.66% | 55 |
|
|
2019
Q1 | $8.05M | Sell |
89,516
-23,664
| -21% | -$2.05M | 0.51% | 62 |
|
|
2018
Q4 | $9.43M | Sell |
113,180
-45,948
| -29% | -$4.31M | 0.68% | 54 |
|
|
2018
Q3 | $17.2M | Buy |
159,128
+99
| +0.1% | +$10.9K | 1.04% | 38 |
|
|
2018
Q2 | $17.5M | Sell |
159,029
-3,506
| -2% | -$365K | 1.02% | 39 |
|
|
2018
Q1 | $16.3M | Sell |
162,535
-2,449
| -1% | -$251K | 1.05% | 36 |
|
|
2017
Q4 | $16.2M | Buy |
164,984
+653
| +0.4% | +$61.9K | 1.03% | 40 |
|
|
2017
Q3 | $15.4M | Buy |
164,331
+8,742
| +6% | +$928K | 1.04% | 39 |
|
|
2017
Q2 | $17.3M | Buy |
155,589
+15,684
| +11% | +$1.66M | 1.13% | 27 |
|
|
2017
Q1 | $13.8M | Sell |
139,905
-14,193
| -9% | -$1.35M | 0.96% | 42 |
|
|
2016
Q4 | $14.2M | Buy |
154,098
+44,093
| +40% | +$3.8M | 0.92% | 45 |
|
|
2016
Q3 | $9.31M | Sell |
110,005
-2,933
| -3% | -$246K | 0.6% | 74 |
|
|
2016
Q2 | $9.19M | Sell |
112,938
-5,600
| -5% | -$426K | 0.63% | 65 |
|
|
2016
Q1 | $8.47M | Sell |
118,538
-3,776
| -3% | -$253K | 0.58% | 72 |
|
|
2015
Q4 | $8.7M | Sell |
122,314
-304,396
| -71% | -$20.5M | 0.49% | 79 |
|
|
2015
Q3 | $26.2M | Buy |
426,710
+146,422
| +52% | +$10.2M | 1.61% | 11 |
|
|
2015
Q2 | $20.3M | Buy |
280,288
+265,638
| +1,813% | +$19.6M | 1.04% | 28 |
|
|
2015
Q1 | $1.13M | Buy |
+14,650
| New | +$1.05M | 0.07% | 125 |
|
Other funds holding DGX
EIG
Copeland Capital Management's DGX Position: Q2 2026 in Review
Copeland Capital Management reduced its Quest Diagnostics (DGX) stake by 6.8% in Q2 2026, selling an estimated $2.07M and leaving 144,784 shares worth $30.7M. The position accounts for 0.63% of the portfolio, ranked #63.
Copeland Capital Management first reported a position in DGX in Q1 2015 and has held it in 46 quarters since. The position peaked at $33.2M in Q1 2025. 1,099 funds tracked by Wall St. Rank hold DGX as of Q2 2026.
- Copeland Capital Management held 144,784 shares of Quest Diagnostics worth $30.7M as of Q2 2026.
- Copeland Capital Management sold 10,564 Quest Diagnostics shares in Q2 2026, an estimated $2.07M.
- Quest Diagnostics made up 0.63% of Copeland Capital Management's portfolio in Q2 2026, its #63 holding.
- Copeland Capital Management first reported a position in Quest Diagnostics in Q1 2015 and has held it in 46 quarters since.
- Copeland Capital Management's Quest Diagnostics position peaked at $33.2M in Q1 2025.
- 1,099 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.
Based on Copeland Capital Management's 13F filing for Q2 2026, filed 4 Aug 2026.